Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II iberdomide maintenance after ASCT in newly diagnosed multiple myeloma
2024-512354-21-00Phase 2Authorised
- Sponsor
- European Myeloma Network
- Start
- Oct 2024
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 4
01
Overview
Phase 2, single-arm trial of iberdomide in multiple myeloma (MM), sponsored by European Myeloma Network. Primary endpoint: Response improvement rate within 6 months. Planned start Oct 2024; status: authorised.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-512354-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512354-21-00.